Promoter holding
64.27%
SB
Stelis Biopharma - Due diligence report
A 360° intelligence report on Stelis Biopharma: trust score, financial health, credit view, compliance, directors, growth and distress signa…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Stelis Biopharma — 360° Intelligence Report
Generated from MCA filings & public records74/100
Trust Score
Moderate
Stelis Biopharma is assessed as Moderate with a Trust Score of 74/100. Stelis Biopharma is an active public limited indian non-government company incorporated in 2007, operating in the Chemicals sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.
Report generated on 01 Oct 2026 from the latest processed filings. Onesource Specialty Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
74/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
63/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
60/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
70/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
90/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Consolidated · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 70/100 Moderate
- Moderate gearing (D/E 38%).
- Externally credit-rated (A+).
Charges position: 20 open (3,364.09 cr) · 12 satisfied (1,444.82 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 21 | 48.0 cr |
| Yes Bank Limited | 3 | 48.0 cr |
| Idbi Trusteeship Services Limited | 3 | 48.0 cr |
| Export Import Bank Of India | 2 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
| Standard Chartered Bank | 1 | 48.0 cr |
Compliance Score: 63/100 Moderate
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2025).
- Litigation present in 1 court forum(s).
- 1 auditor resignation(s) filed - latest: Gnanoba & Bhat on 2016-08-09.
- Delayed payments to MSME suppliers disclosed (1301 disclosure(s)).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| BHARAT DHIRAJLAL SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ANURAG BHAGANIA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Allada Trisha | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Rashmi Harshadrai Barbhaiya | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NEERAJ SHARMA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| CLAUDIO DR. ALBRECHT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Anurag Bhagania | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Allada Trisha | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEBARATI SEN | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARUN KUMAR PILLAI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Vijay Paul Karwal | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Colin Bond Michael | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 12 directors on the board.
- No disqualified or deactivated DINs.
- 1 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2025)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
1
Group entities
1
Capital events
90 allotment(s) · 3 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Biolexis Private Limited | Subsidiary Company | 74.00% |
| Stelis Biopharma Uk Private Limited | Subsidiary Company | 74.00% |
| Stelis Pte Ltd, Singapore | Subsidiary Company | 74.00% |
Key managerial personnel: ANURAG BHAGANIA (CFO) · NEERAJ SHARMA (Managing Director) · Anurag Bhagania (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 90 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Asset base grew 24% - capacity expansion.
EPFO headcount growing - hiring signal.
Operating for 19+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 0.86 in a year.
20 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 23.89 cr.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence71/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 20 open charge(s) of 3,364.09 cr already registered.
- Compliance gaps should be priced into terms.
Investor view76/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events12 Jun 2026
Charge created
Others - 310.58 cr
03 May 2026
Charge satisfied
Others
28 Jan 2026
Charge created
Others - 75.00 cr
27 Dec 2025
Charge created
Yes Bank Limited - 100.00 cr
15 Dec 2025
Charge created
Others - 100.00 cr
06 Dec 2025
Charge satisfied
Others
13 Nov 2025
Charge created
Others - 1,342.49 cr
25 Sep 2025
Charge created
Others - 150.00 cr
22 Sep 2025
Charge created
Others - 100.00 cr
Last AGM held
Annual general meeting
29 Aug 2025
Charge created
Standard Chartered Bank - 125.00 cr
23 Jun 2025
Director appointed
Colin Bond Michael (Director)
19 Jun 2025
Charge created
Yes Bank Limited - 50.00 cr
25 Apr 2025
Charge created
Others - 150.00 cr
23 Apr 2025
Charge created
Others - 130.00 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 61% over the last 4 financial year(s).
Net profit margin moved from 38% to 1.42.
Debt-to-equity stands at 2.1x - manageable leverage.
Net worth is positive.
12 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A+ from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 90 security allotment(s) - amounts available in the full report.
16 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Credo | U20119GJ1995PLC064782 | Ahmedabad, Gujarat, India |
| Rishab Healthcare Private Limited | U51397CH2005PTC027979 | Chandigarh, Chandigarh, India |
| Rathi Graphic Technologies Limited | L26960UP1991PLC013770 | Ghaziabad, Uttar Pradesh, India |
| R R Paint Private Limited | U24222MH1957PTC010996 | Mumbai, Maharashtra, India |
| Norris Medicines | L24230GJ1990PLC086581 | Ankleshwar, Gujarat, India |
| Syncom Formulations | L24239MH1988PLC047759 | Mumbai, Maharashtra, India |
| Dream Green Petro-Chem Private Limited | U24296MH2014PTC252999 | Nashik, Maharashtra, India |
| Colinz Laboratories | L24200MH1986PLC041128 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Stelis Biopharma before audits and certifications: compliance score 63/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Stelis Biopharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 70/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 90/100, margin trends, ownership structure and peer set for Stelis Biopharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 74/100, distress signals and MSME payment-delay disclosures - know whether Stelis Biopharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Stelis Biopharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Stelis Biopharma an active company?
Stelis Biopharma has MCA status “Active” with a compliance score of 63/100 (Moderate).
Is Stelis Biopharma financially healthy?
Stelis Biopharma has a Financial Health Score of 60/100 (Moderate) based on its filed financial statements.
Should I do business with Stelis Biopharma?
Its overall Trust Score is 74/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Stelis Biopharma?
Promoters hold the largest single block of equity - exact percentages are in the full report. 12 active director(s) are on record.
Does Stelis Biopharma have loans or charges against its assets?
20 open charge(s) are registered against its assets, and 12 earlier charge(s) stand satisfied.
Is Stelis Biopharma up to date with its ROC filings?
Balance sheet slightly behind (Mar 2025). Overall compliance score: 63/100 (Moderate).
Is it risky to lend to Stelis Biopharma?
Its Credit Risk Score is 70/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
